Savella Tablet, Film Coated
NDC Package 0456-1550-63
Package Information
Savella (milnacipran hydrochloride) tablets is milnacipran is used to treat pain caused by a condition called fibromyalgia that affects the muscles, tendons, ligaments, and supporting tissues. This formulation utilizes a tablet, film coated delivery system. Marketed by Allergan, Inc., this product is identified by NDC 0456-1550 and is authorized under FDA application NDA022256.
Identification & Billing
- RxCUI: 833135 - milnacipran HCl 100 MG Oral Tablet
- RxCUI: 833135 - milnacipran hydrochloride 100 MG Oral Tablet
- RxCUI: 833139 - Savella 100 MG Oral Tablet
- RxCUI: 833139 - milnacipran hydrochloride 100 MG Oral Tablet [Savella]
- RxCUI: 833141 - milnacipran HCl 12.5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0456 - Allergan, Inc.
- 0456-1550 - Savella
- 0456-1550-63 - 10 BLISTER PACK in 1 BOX, UNIT-DOSE / 10 TABLET, FILM COATED in 1 BLISTER PACK (0456-1550-11)
- 0456-1550 - Savella
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0456-1550). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0456-1550-63 identifies a specific commercial package of 10 blister pack in 1 box, unit-dose / 10 tablet, film coated in 1 blister pack (0456-1550-11) of Savella, a human prescription drug labeled by Allergan, Inc.. This tablet, film coated is formulated for oral use and contains milnacipran hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allergan, Inc. on April 17, 2009. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Milnacipran is used to treat pain caused by a condition called fibromyalgia that affects the muscles, tendons, ligaments, and supporting tissues. This medication is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by helping to restore the balance of certain natural substances in the brain (neurotransmitters).
How is this Allergan, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00456155063. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.